1 Department of Psychiatry, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
2 Department of Medicine (Neurology) Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
3 Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada.
4 University of Toronto, Baycrest Health Sciences, Toronto, Ontario, Canada.
5 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
6 Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Laval, Québec, Canada.
7 Departments of Medicine, and Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.
8 Gait and Brain Lab, Parkwood Institute, London, Ontario, Canada.
9 Dalhousie University, Halifax, Nova Scotia, Canada.
10 Neurosurgery and Psychiatry, McGill Centre for Studies in Aging, Montreal, Quebec, Canada.
11 Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
12 Alzheimer Society of Canada, Toronto, Ontario, Canada.
13 McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, PERFORM Centre, Concordia University, Montreal, Quebec, Canada.
14 Department of Family Medicine, McGill University, Montreal, Quebec, Canada.
15 Alzheimer Disease Research Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada.

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Alzheimers Dement. 2020 Jul 29;:

Authors: Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants

Abstract

Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTD) have provided evidence-based dementia guidelines for Canadian clinicians and researchers. We present the results of the 5th CCCDTD, which convened in October 2019, to address topics chosen by the steering committee to reflect advances in the field, and build on previous guidelines. Topics included: (1) utility of the National Institute on Aging research framework for clinical Alzheimer's disease (AD) diagnosis; (2) updating diagnostic criteria for vascular cognitive impairment, and its management; (3) dementia case finding and detection; (4) neuroimaging and fluid biomarkers in diagnosis; (5) use of non-cognitive markers of dementia for better dementia detection; (6) risk reduction/prevention; (7) psychosocial and non-pharmacological interventions; and (8) deprescription of medications used to treat dementia. We hope the guidelines are useful for clinicians, researchers, policy makers, and the lay public, to inform a current and evidence-based approach to dementia.

PMID: 32725777 [PubMed - as supplied by publisher]